Key Trends in Offshoring Pharmaceutical R&D: Company strategies, emerging markets and impact on ROI

‘Key Trends in Offshoring Pharmaceutical R&D' is a report published by Business Insights that evaluates the offshore R&D strategies that can reduce development times and improve productivity, with analysis of a variety of strategic partnerships, academic collaborations, and outsourcing opportunities.

Infectious Diseases Pharma Market Overview - Strategic perspectives in portfolio management

A total of 11 companies make up the top five across each of the four ID sectors, their core competencies ranging from a single disease area to generics prowess, producing a comprehensive portfolio to providing a specific offerings corresponding to highest unmet need. This report characterises the key players in each sector, and their approach to maximising their returns from a pressurised sector.

Gastric Cancer - Targeted therapies compete for first-to-market status

Gastric cancer incidence in 2009 is forecast to be 197,000 in the seven major pharmaceutical markets (US, Japan, Germany, France, Italy, Spain, and UK). Although, the global incidence has decreased in recent years, mortality remains high, particularly in the US and Europe. Therefore, predictably a high unmet need remains for effective therapies to improve mortality.

Pharmaceuticals: Global Industry Almanac

Datamonitor's Pharmaceuticals: Extended Global Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.

Pharmaceuticals - Top 5 Emerging Markets Industry Guide

Datamonitor's Pharmaceuticals - Top 5 Emerging Markets Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the Top 5 Emerging markets (Brazil, China, India, Mexico and South Africa). The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Pharmaceuticals - North America (NAFTA) Industry Guide

Datamonitor's Pharmaceuticals - North America (NAFTA) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the North American Free Trade Agreement (United States, Canada, and Mexico) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

Datamonitor's Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide

Datamonitor's Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, China) Pharmaceuticals industry. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Schizophrenia - Second generation depots protect market value

Schizophrenia is a chronic and severe mental health disorder affecting around 4.6 million schizophrenia sufferers across the seven major markets. Currently led by oral branded atypical antipsychotics, the schizophrenia market will undergo some big changes over the period 2008/2017. Prospective players can expect to face stiff competition from generic versions of all currently branded drugs.

Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors

The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS blockbuster brands, the market continues to offer a wealth of lucrative opportunities for all types of drug manufacturer.

Pricing and Reimbursement in The United Arab Emirates

The healthcare sector in the emirates of Abu Dhabi and Dubai is undergoing drastic changes as a result of the structural and financing reforms that will impact all major actors in the healthcare sector.

Vaccine administration technologies - Beyond needles

Novel vaccine administration technologies have the potential to improve vaccine developers' commercial competitiveness and to increase vaccination safety and convenience. This report assesses key strategies, technologies and products for novel dermal and mucosal vaccine administration. It also provides an overview of opportunities and challenges for the sector and a future outlook.

Pharma 2020: The vision

Which path will you take?

Demand for effective medicines is rising, as the population ages, new medical needs emerge and the disease burden of the developing world increasingly resembles that of the developed world. The E7 countries - Brazil, China, India, Indonesia, Mexico, Russia and Turkey - are also becoming much more prosperous, with real gross domestic product (GDP) projected to triple over the next 13 years. By 2020, the E7 could account for as much as one-fifth of global sales.

Donwnload free 52 pages report at our Download Section

Virtual R&D - Which path will you take?

Pharma is at a pivotal point in  its evolution. Social, demographic  and economic milieu in which the  industry operates is undergoing huge  changes. These challenges have  been compounded by the dearth of  good new compounds in its pipeline.

Donwnload free 24 pages report at our Download Section  

Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges

In recent years, Pharma has begun to adapt its business model in response to growing industry constraints and the decline of the primary-care focused blockbuster therapy. This process of change has recently been disrupted by unprecedented challenges caused by the global economic downturn, and by President Obama's planned overhaul of the US healthcare system.

Generic Benchmarking: Brand Erosion at Patent Expiry

Not only is Pharma facing a continued slow down in sales growth in the seven major markets, but erosion of branded drugs by generics follow patent expiry is increasing, driven by evolving payer initiatives to incentivize generic use.

Pipeline Insight: Molecular Targeted Cancer Therapies - More pipeline activity, less product differentiation

Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, commercial and strategic challenges are continuing to emerge.

Novartis AG: PharmaVitae Profile

This analysis examines the historical and forecast performance for Novartis in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.